0.76
0.76 (0.48%)
As of Nov 28, 2023
Cohbar, Inc. [CWBR]
Source:
Company Overview
CohBar (CohBar, we, us, our, its or the Company) is a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. Our novel approach is built on the key insights of the Companys founders that certain mitochondrially encoded peptides produce effects that are not limited to local regulation within the mitochondria and may have important roles to play in critical systemic biological pathways.
| Country | United States |
| Headquarters | menlo park, california |
| Phone Number | (650) 446-7888 |
| Industry | manufacturing |
| CEO | Joseph Sarret |
| Website | http://www.cohbar.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-4.4 |
| Net Income | $-4.3 |
| Net Cash | $0.3 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -30% |
| Profit as % of Stockholder Equity | -45.6% |
Management Effectiveness
| Return on Equity | -45.6% |
| Return on Assets | -34.6% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $12.5 |
| Total Liabilities | $3 |
| Operating Cash Flow | $-3.4 |
| Investing Cash Flow | $3.7 |
| Financing Cash Flow | $0 |
